NRP2 and interstitial lung disease: Efzofitimod is a first-in-class biologic immunomodulator targeting Nrp2 that is in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs [154].